Vaso Corporation Announces Financial Results for Third Quarter of 2026
Key Highlights
- ➤Q3 revenue fell 12.9% to $10.8 million year over year
- ➤Q3 net income declined to $568 thousand from $1.7 million
- ➤Adjusted EBITDA dropped to $691 thousand from $1.3 million
- ➤Operating cash flow reached $6.5 million through nine months
- ➤Vaso completed its exit from network and IT services businesses
Expert Statements
Jun Ma, President and Chief Executive Officer of Vaso Corporation
“For the third quarter of 2026, the Company recorded net income of $568 thousand on total revenue of $10.8 million, as compared to net income of $1.7 million on total revenue of $11.4 million for the same quarter of the prior year, with healthcare IT and network services businesses excluded from both periods, as we divested the two businesses in November 2025 and July 2026, respectively.”
Jun Ma, President and Chief Executive Officer of Vaso Corporation
“Also, when excluding the IT segment, gross profit for the quarter was $8.6 million, a decrease of $599 thousand, or 6.5%, year over year, mainly as a result of lower revenue.”
Jun Ma, President and Chief Executive Officer of Vaso Corporation
“Cash generated from operating activities for the first nine months of 2026 was $6.5 million.”
Jun Ma, President and Chief Executive Officer of Vaso Corporation
“Total deferred revenue was $41.5 million at the end of the third quarter of 2026, an increase of $2.1 million, or 5.4%, from September 30, 2025.”
Jun Ma, President and Chief Executive Officer of Vaso Corporation
“With the completion of the Company’s exit from the network and IT services business in the third quarter of 2026, the Company now continues to operate in the professional sales service segment and proprietary medical device segment. We anticipate higher efficiency and profitability going forward as the Company can better focus its resources on the development of its businesses in the healthcare sector.”
PLAINVIEW, N.Y., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a business portfolio in professional sales services and proprietary non-invasive medical products, today announced its operating results for the three months ended September 30, 2026.
“For the third quarter of 2026, the Company recorded net income of $568 thousand on total revenue of $10.8 million, as compared to net income of $1.7 million on total revenue of $11.4 million for the same quarter of the prior year, with healthcare IT and network services businesses excluded from both periods, as we divested the two businesses in November 2025 and July 2026, respectively,” commented Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Also, when excluding the IT segment, gross profit for the quarter was $8.6 million, a decrease of $599 thousand, or 6.5%, year over year, mainly as a result of lower revenue.”
Get started
Create a free account to read the full story.
